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Abstract
Background: Screening mammography has had a positive impact on breast cancer mortality but
cannot detect all breast tumors. In a small study, we confirmed that low power magnetic resonance
imaging (MRI) could identify mammographically undetectable tumors by applying it to a high risk
population. Tumors detected by this new technology could have unique etiologies and/or
presentations, and may represent an increasing proportion of clinical practice as new screening
methods are validated and applied. A very important aspect of this etiology is genomic instability,
which is associated with the loss of activity of the breast cancer-predisposing genes BRCA1 and
BRCA2.  In sporadic breast cancer, however, there is evidence for the involvement of a different
pathway of DNA repair, nucleotide excision repair (NER), which remediates lesions that cause a
distortion of the DNA helix, including DNA cross-links.
Case presentation: We describe a breast cancer patient with a mammographically undetectable
stage I tumor identified in our MRI screening study. She was originally considered to be at high risk
due to the familial occurrence of breast and other types of cancer, and after diagnosis was
confirmed as a carrier of a Q1200X mutation in the BRCA1 gene. In vitro analysis of her normal
breast tissue showed no differences in growth rate or differentiation potential from disease-free
controls. Analysis of cultured blood lymphocyte and breast epithelial cell samples with the
unscheduled DNA synthesis (UDS) assay revealed no deficiency in NER.
Conclusion: As new breast cancer screening methods become available and cost effective,
patients such as this one will constitute an increasing proportion of the incident population, so it is
important to determine whether they differ from current patients in any clinically important ways.
Despite her status as a BRCA1 mutation carrier, and her mammographically dense breast tissue, we
did not find increased cell proliferation or deficient differentiation potential in breast epithelial cells
from this patient which might have contributed to her cancer susceptibility. Although NER
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patients, analysis of blood cultured lymphocytes and breast epithelial cells for this patient proves
definitively that heterozygosity for inactivation of BRCA1 does not intrinsically confer this type of
genetic instability. These data suggest that the mechanism of genomic instability driving the
carcinogenic process may be fundamentally different in hereditary and sporadic breast cancer,
resulting in different genotoxic susceptibilities, oncogene mutations, and a different molecular
pathogenesis.
Background
A reduction in breast cancer mortality has been observed
in recent years that has been partially attributed to the
widespread adoption of screening mammography [1].
Traditional screening mammography, however, fails to
detect 15% of incident cancers [2]. New, complementary
imaging techniques are therefore under development that
may increase the accuracy of primary screening. We per-
formed a small study to validate the use of low power
magnetic resonance imaging (MRI) to prospectively detect
breast alterations and malignancy and to determine the
feasibility of applying this technique to a high-risk popu-
lation [3]. We present here a subject from that study
whose early stage tumor was not detectable by
mammography.
This patient was enrolled in the screening study due to her
family history of breast and other neoplasias. After tumor
diagnosis, she was determined to be heterozygous for a
putative inactivating mutation in the BRCA1 gene. In
addition, she had dense breast tissue, an impediment to
mammography that is in itself a risk factor for breast can-
cer [4]. Breast development and lactational differentiation
also appear to individually modify breast cancer risk, with
early term pregnancy conferring a persistent protective
effect [5]. Exposure to ionizing radiation, while a lifetime
risk factor for breast cancer, appears to be more dangerous
when it occurs during alveolar differentiation of the breast
at adolescence [6]. Using a novel tissue engineering sys-
tem [7], we therefore examined the growth and differenti-
ation of normal breast epithelial samples from this
patient via live-cell imaging.
The BRCA1 hereditary breast cancer gene has been shown
to be involved in DNA double strand break repair [8,9].
DNA repair defects have also been identified in the
peripheral blood cells of sporadic breast cancer patients
[10-13], but, in this case, it seems to involve a different
pathway of DNA repair, nucleotide excision repair (NER)
[14-16]. We have extended this observation of NER defi-
ciency to the tumor itself, as well as the adjoining non-dis-
eased normal breast tissue [17]. NER is a complex
pathway of DNA repair [18] normally associated with
removal of pyrimidine-pyrimidine intrastrand crosslinks
(“dimers”) caused by exposure to UV light.  NER defi-
ciency is the basis of hereditary xeroderma pigmentosum
(XP) [19], a disease with a 1200-fold increase in incidence
of skin cancer [20].  The signal for activation of the NER
pathway is actually very general; any lesion causing a dis-
tortion in the DNA helix, including crosslinks caused by
oxidative radicals, certain types of mismatches (purine-
purine or pyrimidine-pyrimidine) and so called “bulky”
adducts caused by phase I metabolism of polyaromatic
hydrocarbons [21]. It has recently been shown that
BRCA1 expression can enhance NER activity, although
this analysis was not performed in breast cells [22,23]. We
therefore applied the functional unscheduled DNA syn-
thesis (UDS) assay for NER capacity to multiple samples
of normal tissue from this patient, to determine whether
haploinsufficiency for BRCA1 was a mechanism of NER
deficiency. We have developed a method to reliably cul-
ture non-diseased breast tissue (with a success rate of
100%) and breast tumors (with a success rate of 85%)
[7,17].
Case presentation
We describe a breast cancer patient whose tumor was
detected by MRI. She was enrolled into a pilot screening
study of low power MRI due to her familial risk. She had
mammographically dense breasts and her tumor was
undetectable mammographically.
Patient description
The patient was a 35.7 year old woman who presented
with a very strong family history of breast cancer as
depicted in Figure 1, and negative physical and mammo-
graphic examination. She had extremely dense breast tis-
sue bilaterally by mammography as well as fibrocystic
breast tissue by physical examination. She had no previ-
ous personal history of breast biopsy or abnormal
mammograms.
Risk profile
The 5 year breast cancer risk for this patient as calculated
by the BRCAPRO model was 5.7%, and her probability of
being a BRCA1 or BRCA2 carrier was 0.47. The Gail model
risk assessment was calculated using the following infor-
mation: Race-Caucasian; Age-35; Age at first menses-12;
Age at first live birth-nulliparous; Number of first-degree
relatives with breast cancer-2; Number of previous breastPage 2 of 11
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her lifetime risk was 31.3%.
Genetic testing
Following genetic counseling, the patient elected to
undergo DNA sequencing of the BRCA1 and BRCA2
genes, which revealed a Q1200X truncation mutation in
one of her BRCA1 alleles. The C to T mutation at codon
1200 in exon 11 results in the change of the amino acid
glutamine to a stop codon with resulting protein trunca-
tion and loss of function. Exon 11 is the largest exon in
BRCA1 and has the highest frequency of reported muta-
tions. The Q1200X mutation has been independently
observed several times [24].
Imaging
The bilateral screening mammogram was compared to
previous films from another hospital. The breast tissue
was described as heterogeneously dense, thus lowering
the sensitivity. There were no masses, significant calcifica-
tions or other findings and the mammogram was inter-
preted as negative bilaterally. A one-year follow-up was
recommended.
The patient was then MRI scanned as previously described
[3], with pre- and post-gadolinium enhancement images
evaluating both breasts simultaneously in the axial plane.
In the upper-outer left breast there was a small (approxi-
mately 1 cm), round, well-demarcated enhancing lesion.
Pedigree of the patient (indicated by arrow)Figu  1
Pedigree of the patient (indicated by arrow). She, one maternal aunt and one maternal cousin had breast cancer diag-
nosed at 36, 44 and 41 years old, respectively, as indicated by the half-filled symbols, and her aunt died of the disease. Her 
cousin underwent lumpectomy followed by chemotherapy, radiotherapy and is presently on tamoxifen. Her mother had breast 
cancer in both breasts, diagnosed at ages 41 and 42, as indicated by the completely filled symbol. She underwent bilateral mas-
tectomy and hysterectomy followed by chemotherapy and radiotherapy and died of the disease at age 44. A second maternal 
aunt was diagnosed with colon cancer at age 52 (light half-filled symbol) and breast cancer at age 55 (dark half-filled symbol). 
Based on this pattern of familial cancer the patient was considered to be at high risk of developing breast cancer and was 
entered into the low power MRI screening validation and feasibility study. Following her diagnosis, she was confirmed as carry-
ing a Q1200X mutation in the BRCA1 gene.Page 3 of 11
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injection and the delayed contrast enhanced subtraction
images. The lesion appeared to accumulate contrast to a
greater extent on the delayed subtraction images with an
additional lesion adjacent to the first. In the medial aspect
of the mid right breast, there were several small punctate
areas of enhancement on both the immediate and delayed
subtraction views. Also in the right breast just above the
nipple level medial and close to the chest wall an addi-
tional enhancing lesion was seen. This lesion was approx-
imately 1.5 cm, round, well-demarcated and continued to
accumulate contrast on the delayed subtraction images.
This lesion appeared to have a small non-enhancing
septation.
Core biopsies
Under ultrasound, the lesion of concern in the left breast
was identified and biopsied, as well as one lesion in the
right breast (Figure 2). The core biopsy of the left breast
revealed infiltrating ductal carcinoma in 2 of 5 core frag-
ments; high nuclear grade, with no lymphatic invasion
seen. The core biopsy of the right breast demonstrated
benign pathology, specifically, fibrosis with focal ductal
epithelial hyperplasia.
Final pathology, treatment plan and outcome
Although a surgical candidate for lumpectomy and radia-
tion, the patient chose to undergo left modified radical
mastectomy with left axillary lymph node dissection and
contralateral prophylactic total mastectomy because of
her genetic risk status. The pathology in the left breast was
consistent with the imaging and core biopsy in size and
description. Tumor size was 8 mm in greatest dimension,
nuclear grade III, ER/PR and Her2/neu negative, and the
nodal status (0/4) was negative (stage TIaN0M0). The
patient underwent 4 cycles of chemotherapy and has been
reportedly healthy since. Because of the positive BRCA1
mutation results, she subsequently underwent prophylac-
tic bilateral salpingo-oophorectomy.
Live-cell analysis of tissue explant cultures
A number of life history factors have been associated with
breast cancer incidence that are widely interpreted as rep-
resenting lifetime exposure of the breast tissue to estro-
gen-induced mitogenesis [25]. An alternative
interpretation, based on epithelial cell differentiation,
suggests that lactational differentiation, such as occurs
during term pregnancy, confers resistance to carcinogene-
sis [26,27]. We have developed a novel human mammary
epithelial (HME) tissue engineering system wherein many
aspects of organotypic differentiation are reiterated in
vitro [28]. In this system, breast epithelial cells initially
retain cell-to-cell contact while they proliferate, then
undergo an architectural reorganization, first to form
three-dimensional mammospheres, and later vast net-
works of branching ductal and lobular structures. Tumor
and some pre-neoplastic samples fail to form such archi-
tecture. Normal tissue from this patient, who is both a
BRCA1 mutation carrier and has dense breasts, was evalu-
ated to determine whether either of these factors affected
de novo differentiation in this system. Four discrete pieces
of fresh tissue were provided for live-cell analysis from
each of the patient's ipsilateral and contralateral breasts.
In the case of the ipsilateral breast, this tissue was pro-
vided at increasing distance from the tumor margin in 1
cm increments. All of these normal samples attached and
grew in our culture system and were examined for cell-to-
cell interactions and morphology over a period of one
month. In the context of breast reduction explant cultures
from 22 patients with no breast disease, these patient
samples manifested typical mixtures of fibroblastic and
epithelial cells. After several days in culture without pas-
saging, the epithelial cells began to self-organize, initially
forming three-dimensional mammospheres (Figure 3A),
and, after 2 weeks in culture, more complex pre-ductal lin-
ear columns of epithelial cells (Figure 3B). The tissue
Ultrasound of the MRI-detected lesionFigure 2
Ultrasound of the MRI-detected lesion. Following MRI, 
the patient was scheduled for ultrasound to identify the 
questionable lesions seen on MRI for possible core biopsy. 
Under ultrasound the lesion of concern was identified and 
biopsied at the 1:00 location in the left breast. Additionally, 
one lesion seen by MRI in the right breast at the 4:00 loca-
tion was identified and biopsied.Page 4 of 11
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behavior (Figure 3). Tissue cultured from a contempora-
neous disease-free control and the contralateral breast of
a sporadic breast cancer patient showed similar morphol-
ogy and architecture (data not shown).
Cell growth kinetics
It has been suggested that the association between breast
density and risk of breast cancer is due to increased cell
proliferation [29]. One measure of cell growth and viabil-
ity is the S-phase index (SPI) or the percentage of cells
incorporating radiolabeled thymidine over a specific incu-
bation period (in our case, 2 hours). In a previous study
with 22 normal breast reduction epithelium [BRE] cul-
tures we observed a wide range of proliferation rates, with
SPI ranging from a low of 0.2% to a high of 46.0% (mean
of 18.3 ± 2.6%) [30]. The contemporaneous control sam-
ple from a disease-free breast reduction patient had an SPI
of 30.9%, at the higher end of this normal range. The ipsi-
lateral and contralateral tissue samples from the heredi-
tary breast cancer patient exhibited SPI of 26.6% and
26.2%, respectively, placing them at slightly over the 70th
percentile for growth rate. The contralateral sample from
the sporadic breast cancer patient had an SPI of 17.0%,
placing it slightly under the 50th percentile. Thus, all of
these breast cancer patient samples appeared to grow well
in our system, with SPI well within the range of our nor-
mal samples. The similarity of the SPI values from the two
samples from the BRCA1 mutation carrier does not
appear to be accidental; the chances of selecting two sam-
ples from the normal population with values as close or
closer is very small (P = 0.026).
Functional analysis of NER capacity
Peripheral blood lymphocytes and normal breast epithe-
lial tissue from the hereditary cancer patient were then
cultured for performance of the functional UDS assay,
which requires living cells for radiolabel incorporation
during DNA repair synthesis following UV exposure. This
assay is diagnostic for the inherited cancer-prone disease
XP, where it is usually performed in lymphocytes or skin
fibroblasts. Our novel HME tissue engineering system
allows us to apply the assay to breast epithelial cells, and
we have previously demonstrated tissue-specificity in the
NER capacity of these cells in normal samples from
patients undergoing breast reduction mammoplasty [30].
Patient data is therefore expressed relative to the average
of our breast reduction controls.
Analysis of cultured blood lymphocytes from the patient
established that they had normal NER capacity (99.6% of
the average of our 33 normal samples) (Figure 4). This is
well above the cut-off established in our sporadic breast
cancer population, < 70% average normal activity, which
when applied to our cases and controls yielded a
Micrographs of the non-diseased primary human mammary epithelial (HME) cultures from the BRCA1 mut tion carrierFigure 3
Micrographs of the non-diseased primary human 
mammary epithelial cultures (HMEC) from the 
BRCA1 mutation carrier. A) Contralateral breast – A 
cluster of epithelial cells called a mammosphere is shown on 
the left center of the image sitting on a field of fibroblasts. B) 
Ipsilateral breast – The original fresh tissue block from which 
this culture was derived was located 4 cm from the infiltrat-
ing ductal carcinoma. The structure shown is a cluster of 
rounded epithelial cells manifesting a column configuration 
called "pre-ductal linearization". Both images were captured 
under Differential Interference Contrast (DIC) optics on a 
Zeiss Axiovert 100 microscope at a total of 140x 
magnification.Page 5 of 11
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dependence had been noted in the analysis of the UDS
data of the normal controls (P = 0.059) [30]; addition of
the patient sample supports this trend, but it still fails to
reach significance (P = 0.056).
The functional NER assay was then applied to the contem-
poraneous disease-free breast reduction control sample,
one sample each from the ipsilateral and contralateral
breasts of the patient, and to a sample from the contralat-
eral breast of an apparently sporadic breast cancer patient.
The NER of the BRE non-diseased control was 1.82 times
the average of our normal data set for this tissue and
within the range of normal. The NER capacity of the ipsi-
lateral breast epithelial sample was 1.05 times the average
of our population of BRE controls, clearly exhibiting no
overt DNA repair deficiency (Figure 5). The contralateral
sample was very similar, with an NER capacity of 1.17
times BRE normal. Although the NER values of these two
samples from the same patient are similar, they are not
close enough to distinguish themselves as coming from
the same individual (P = 0.16). The NER capacity of the
contralateral sample from the sporadic breast cancer
patient was 1.62 times the average of the BRE controls,
also in the normal range.
Our earlier analysis of NER in our normal population
revealed no effects of age or cell proliferation (as repre-
sented by the SPI). All of these additional patient samples
are consistent with those results.
Discussion
At least two types of breast tumors are not accurately
detected by traditional screening mammography: "inter-
val" tumors that arise quickly between screenings, and
tumors whose density is not sufficient to distinguish them
from the surrounding normal tissue. The latter situation is
more likely to occur in women with dense normal breast
tissue, which, in turn, is more typical of younger women.
Thus, mammographically undetectable tumors may have
a number of characteristics, such as fast growth, low
density, early onset and/or occurrence in dense breasts
that might distinguish them from mammographically
detectable tumors in terms of molecular etiology and clin-
ical parameters of prognosis and response. The present
patient had an early onset breast tumor, but had both
hereditary susceptibility due to her BRCA1 mutation and
dense breasts, so her presentation is not unusual in this
context. It is possible that breast tumors detected by com-
plementary screening methods in the future will demon-
strate unique clinical and molecular features, when it
becomes feasible to perform such screening in the general
population.
Since the BRCA1 gene product is known to play a role in
DNA double strand break repair [8,9], it has been
suggested that decreased repair capacity is the basis of the
breast cancer predisposition observed in mutation carriers
[32-35]. Such a cellular phenotype has been difficult to
demonstrate, however [36-39]. An alternate possibility is
that the mutation affects the growth or differentiation of
breast epithelial cells in a manner consistent with cancer
susceptibility. It has been suggested that dense breast tis-
sue is indicative of generalized hyperproliferation that
might promote oncogenesis [29]. Our findings show that
all 8 samples, derived from both the involved and the
uninvolved breasts of a hereditary breast cancer patient
develop normal epithelial architecture in vitro, implying
that the epithelial/stromal (paracrine) interactions neces-
sary for the development of this complex architecture are
intact and normal in BRCA1 heterozygotes despite their
greater risk of breast cancer. The SPI results also indicate
that this non-diseased epithelial tissue falls into the typi-
cal range of normal for BRE control cultures and is dem-
onstrating typical growth in our HME tissue engineering
system.
Comparison of the NER capacity of a PBL sample from our BRCA1 mutation carrier patient with those of a populati n of disease-free c trolsFigur  4
Comparison of the NER capacity of a PBL sample 
from our BRCA1 mutation carrier patient with those 
of a population of disease-free controls. The dark hori-
zontal line indicates the average for the normal population, 
while the dotted lines indicate upper limits for residual NER 
activity in patients with the hereditary NER deficiency disease 
XP (0.50) and the cut-off established in our breast tissue 
study that identified tumors with high sensitivity and specifi-
city (0.70).Page 6 of 11
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ity to UV-induced DNA damage and skin cancer [18-21].
The NER deficiency of XP patients is manifested in other
tissues, however, as shown by their high spontaneous fre-
quency of mutation in blood lymphocytes [40] and the
occurrence of other types of tumors [41]. The observation
that sporadic breast cancer patients have low levels of NER
in peripheral lymphocytes suggests that sporadic breast
cancer is associated with constitutively low levels of NER
[14-16]. Our results from a single patient demonstrate,
however, that while overexpression of BRCA1 may
enhance NER [22], haploinsufficiency for this gene does
not necessarily result in detectable NER deficiency. Since
it is clear that genomic instability is a necessary prerequi-
site for the completion of the complex multi-step carcino-
genic pathway(s) involved in breast cancer, a
fundamental difference in the mechanisms of genomic
instability arising in hereditary and sporadic breast
tumors would be likely to translate into fundamentally
different patterns of molecular pathogenesis that could
impact on clinical management.
The relative NER capacities of tumor and normal tissue
may have important practical implications.  If breast
tumors from hereditary patients exhibit NER deficiency
similar to that observed in sporadic patients, while their
Comparison of the NER capacities of two samples of normal breast epithelium from our BRCA1 mutation carrier patient with th se of a population of dise se-free controls who unde went breat reduction ma moplastyFigure 5
Comparison of the NER capacities of two samples of normal breast epithelium from our BRCA1 mutation car-
rier patient with those of a population of disease-free controls who underwent breast reduction mammo-
plasty. The dark horizontal line indicates the average for the normal population of breast reduction epithelium (BRE), while 
the dotted lines indicate upper limits for residual NER activity in patients with the hereditary NER deficiency disease XP (0.50) 
and the cut-off established in our breast tissue study that identified tumors with high sensitivity and specificity (0.70). The 
patient sample on the left was derived from the ipsilateral (left) breast, while the sample on the right was from the contralateral 
(right) breast.Page 7 of 11
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repair, then the tumors would be hypersensitive to a range
of chemotherapeutic drugs, including alkylating agents
(cyclosphosphamide), cross-linking agents (cis-platinum)
and bulky DNA adducting agents (melphalan).  Individu-
alization of chemotherapy based on some aspect of NER
expression is being pursued in colon [42], testicular
[43,44] and ovarian cancer [45].
Conclusion
This patient and her tumor represent the vanguard of a
new population of early stage breast cancer patients that
will be increasingly diagnosed as new screening technolo-
gies complementary to mammography are validated and
become practicable. We have shown that low power MRI
can detect a stage I tumor in dense breast tissue; the same
technology can also impact upon interval tumors by stag-
gering the procedure with mammography rather than
applying them coincidently. Although we did not observe
obvious differences in the growth rate or differentiation
potential of the dense breast tissue from this patient, we
cannot rule out the possibility that some or all of the
tumors detectable only by complementary screening pro-
cedures will differ from the present clinical experience in
important ways. Our live-cell analysis takes a step toward
defining cellular characteristics that may be useful for can-
cer risk assessment, but we are only beginning to investi-
gate the possibilities of the system. It may be that different
growth conditions, or induction with genotoxic or estro-
genic agents, will allow for the greater differentiation of
breast tissue and tumor behaviours. This technique also
allows for the application of functional assays to patient
samples, as exemplified in this report by the UDS assay for
NER capacity. Those UDS results, although from a single
patient, demonstrate definitively that the constitutively
low NER capacities reported in several sporadic breast
populations do not arise as a pleiomorphic effect of
BRCA1 haploinsufficency. Thus, the basis of genetic insta-
bility, a fundamental element in breast carcinogenesis,
may differ between sporadic and hereditary breast tumors.
This results in different susceptibilities to inducing agents,
mutations in different sets of oncogenes and tumor sup-
pressor genes, and, ultimately, tumors of different molec-
ular etiology that express different clinically relevant
phenotypes.
Methods
Patients and controls
The patient was a 35.7 year old woman with strong family
history of breast cancer recruited into a clinical trial of
MRI screening for young woman at high risk for breast
cancer with dense breast tissue [3]. Gadolinium enhance-
ment images revealed a small 1 cm lesion in the upper-
outer quadrant of the left breast, identified pathologically
as an infiltrating ductal carcinoma. The patient underwent
a modified radical mastectomy of the left breast and chose
to also undergo a contralateral prophylactic total mastec-
tomy. Blood and tissue were obtained for analysis with
consent under Magee-Womens Hospital (of the Univer-
sity of Pittsburgh Medical Center) IRB # MWH-94-108.
Data from this hereditary breast cancer patient were com-
pared to that from two additional patients as well as pre-
viously published controls. The first new control patient
was a 20 year old women undergoing breast reduction
mammoplasty. The second contemporaneous control
patient was a 36 year old woman undergoing cosmetic
surgery on her contralateral breast two years after success-
ful lumpectomy to remove an apparently sporadic stage
IIA breast tumor (2.5 cm, negative for estrogen and pro-
gesterone receptors, 13 lymph nodes negative). She had
undergone standard radiotherapy and chemotherapy with
adriamycin and cyclophosphamide. Histopathological
analysis confirmed that the breast tissue from both of
these control patients was free of cancer and within the
acceptable histological range of normal.
Patient tissue culture and analysis
Fresh tissues from the patient were obtained within 5
hours of surgery. After pathological evaluation, excess tis-
sue not needed for diagnosis was placed into DMEM con-
taining 10% fetal calf serum and 3x antibiotic antimycotic
(Sigma, St. Louis, MO) at 4°C. This tissue was then proc-
essed as described in Latimer et al. [30] and placed into
culture on a diluted form of matrigel (1:1 with DMEM) in
the novel MWRIα medium [7].
Eight samples of the principal patient's tissue were
obtained for culture after bilateral mastectomy surgery.
We were not able to obtain a sample of her tumor,
because it was utilized entirely for clinical diagnosis. We
were able to obtain 4 pieces of histologically normal non-
tumor adjacent tissue at increasing 1 cm intervals from the
tumor margin from her left (ipsilateral) breast. In addi-
tion, we obtained 4 similar pieces of fresh tissue from her
contralateral breast. All were placed into primary explant
(HME) culture.
For analysis of cell growth and in vitro differentiation,
explants were cultured and imaged every second day using
a digital Hamamatsu Orca camera for 30–60 days. Images
were analyzed on a Macintosh G4 computer using QED
imaging software (Media Cybernetics, Inc., Silver Spring,
MD).
Control tissue cultures
Breast reduction mammoplasty tissues were obtained
from patients ages 20–70 at Magee-Womens Hospital
under the above IRB. A neighboring piece of mammo-
plasty tissue (from the same 0.25 cm2 sample) to thatPage 8 of 11
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paraffin. These sections were examined by a pathologist to
verify the histological features and normality of the tissue.
Breast tissue was processed as previously described [30].
Tissue was rinsed three times in PBS containing antibiot-
ics, disaggregated and placed into MWRIα medium [7] on
a thin coat of matrigel. Peripheral blood lymphocytes
(PBLs) were obtained with consent from normal healthy
control subjects ages 20–50 working at Magee-Womens
Hospital or students at the University of Pittsburgh. Fore-
skin fibroblast (FF) tissue was obtained as discarded tissue
from newborn infants after circumcision and utilized
between passages 7 and 10. These control populations
have been previously described in greater detail [30,46].
Breast tissue samples from the two new control patients
were processed in the same manner.
Analysis of S-phase indices
Primary cultures of mammary tissue, established 10–14
days, were labeled with 3H-thymidine for a period of 2
hours followed by a chase with cold thymidine for 2 hours
and then processed for autoradiography. After a 10–12
day exposure, slides were processed and analyzed by two
independent, blinded scorers who evaluated the tissue
samples for the percentage of cells in S phase (character-
ized by complete coverage of the nucleus with silver
grains).
Unscheduled DNA synthesis
NER was measured by autoradiography of unscheduled
DNA synthesis after UV damage (UDS) [47,48]. After a
total of 10–14 days in culture, without passaging, cultures
were irradiated with UV light at 254 nm at a mean fluence
of 1.2 Joules/m2 for 12 seconds in the absence of culture
medium, for a total dose of 14 J/m2. Each sample was rep-
resented by at least two chamber slides. One chamber of
each 2-chamber slide was shielded from the UV dose to be
used as an unirradiated control sample. Primary cultures
had not reached confluence and were still actively grow-
ing at the time the UDS assay was performed. Control FF
were plated subconfluently 2 days before the UDS assay to
insure that they also were not in a quiescent state brought
on by confluence. After UV exposure, all cultures were
incubated in medium supplemented with 10 µCi ml
[3H]methyl-thymidine (~80 Ci mmol-1) (PerkinElmer
Life Sciences, Boston, MA) for 2 hours at 37°C. Labeling
medium was then replaced with unlabeled chasing
medium containing 10-3 M non-radioactive thymidine
(Sigma) and incubated for a further 2 hours to clear radi-
oactive label from the intracellular nucleotide pools. After
incubation in the post-labeling medium, cells were fixed
in 1X SSC, 33% acetic acid in ethanol, followed by 70%
ethanol and finally rinsed in 4% perchloric acid over night
at 4°C. All slides were dried and subsequently dipped in
photographic emulsion (Kodak type NTB2) and exposed
for 10 to 14 days in complete darkness at 4°C.
The length of exposure of emulsion was determined in
each experiment by preparing FF "tester" slides. After 10–
12 days these tester slides were developed and grain
counting was performed. If the nuclei over the foreskin
fibroblasts averaged 50 or more grains per nucleus, then
the rest of the experimental slides were developed. If the
grain count was below this level, the remaining slides
were left to expose 1–3 days longer before being
developed.
Grain counting
After photographic development of emulsion, all slides
were stained with Giemsa, then examined at a total mag-
nification of 1000X on a Zeiss Axioskop under oil emer-
sion for grains located immediately over the nuclei of
non-S phase cells [48]. Local background grain counts
were evaluated in each microscopic field over an area the
same size as a representative nucleus, and this total was
subtracted from the grain count of each nucleus in that
field. The average number of grains per nucleus was quan-
tified for each side of the chamber slide, both unirradiated
and irradiated. The final NER value for each slide was cal-
culated by subtracting the unirradiated mean (grains per
nucleus) from the irradiated mean (grains per nucleus),
after the initial subtraction of local background in each
field. NER was initially expressed as a percentage of the
activity of concurrently analyzed FF. Four FF slides were
scored per experiment, by an average of three counters.
200 nuclei were counted per slide, for a total of 800, with
an average of 61.6 grains/nucleus. Six slides were evalu-
ated for the patient's PBL sample, two by each of three
counters. An average of 195 nuclei were scored per slide
(for a total of almost 1200), with an average of 7.5 grains/
nucleus. Four slides were counted for the contemporane-
ous breast reduction control, two each by two counters.
There were an average of 200 nuclei per slide and 14.1
grains/nucleus. Six slides were scored from the patient's
ipsilateral breast tissue sample, two by each of three inde-
pendent counters, and five slides were counted from the
contralateral sample, again by three independent
counters. An average of just over 100 nuclei were evalu-
ated per slide for each sample, for a total of almost 600
nuclei for the ipsilateral sample and over 500 for the con-
tralateral sample. As the NER capacities indicate, these
samples had very similar counts; about 35 grains/nucleus
for the ipsilateral sample and 28 grains/nucleus for the
contralateral sample. Finally, four slides were counted
from the contralateral sample of a sporadic breast cancer
patient, by three counters. There were an average of 200
nuclei per slide and 29.4 grains per nucleus.Page 9 of 11
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To ensure accuracy and guard against transcription errors,
raw grain counts from the UDS assay were processed inde-
pendently in duplicate, once using StatView (version
5.0.1, SAS Institute, Inc., Cary, NC), and once using the
Data Analysis Toolpack of the Excel 2001 spreadsheet pro-
gram (Microsoft Corp., Redmond, WA). The final count
from slides of the same cell type within the same experi-
ment and developed the same day were averaged together
and expressed as a percentage of concurrently analyzed FF.
These results were then normalized by comparison to the
average for the tissue type control population [48].
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